Inhibitor Therapeutics (OTCMKTS:INTI – Get Free Report) and Stoke Therapeutics (NASDAQ:STOK – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.
Volatility & Risk
Inhibitor Therapeutics has a beta of -0.56, meaning that its share price is 156% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Inhibitor Therapeutics and Stoke Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inhibitor Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Stoke Therapeutics | 0 | 1 | 8 | 1 | 3.00 |
Valuation and Earnings
This table compares Inhibitor Therapeutics and Stoke Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inhibitor Therapeutics | N/A | N/A | -$3.03 million | ($0.01) | -5.90 |
| Stoke Therapeutics | $16.74 million | 28.35 | -$104.70 million | ($2.10) | -4.27 |
Inhibitor Therapeutics has higher earnings, but lower revenue than Stoke Therapeutics. Inhibitor Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Inhibitor Therapeutics and Stoke Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inhibitor Therapeutics | N/A | -70.65% | -40.64% |
| Stoke Therapeutics | -629.90% | -54.45% | -40.77% |
Summary
Stoke Therapeutics beats Inhibitor Therapeutics on 8 of the 12 factors compared between the two stocks.
About Inhibitor Therapeutics
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.
About Stoke Therapeutics
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Inhibitor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibitor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
